Androgen deprivation therapy

Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum...

The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...

Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...

The American Cancer Society estimates that in 2020, there will have been more than 190,000 cases of prostate cancer in...

The Food and Drug Administration ( FDA ) has approved the first oral gonadotropin-releasing hormone ( GnRH ) receptor antagonist,...

The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...

SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...

Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...

Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...

The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...

Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...

For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...

Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...

Radium-223 dichloride ( Ra-233; Xofigo ), a bone targeting alpha radiopharmaceutical, and Enzalutamide ( Xtandi ), are approved for metastatic...

The PROSPER trial has shown a clinically and statistically significant improvement in metastasis-free survival ( hazard ratio, HR=0.292 [ 95%...

The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...

New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (...

Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...

STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of...

Successivi →

MedTV

Tumore al polmone: valutazione geriatrica multidimensionale
Depressione maggiore: rischio di epatotossicità con Agomelatina
Epatite C: gravi reazioni cutanee dopo trattamento con Telaprevir, PegInterferone alfa e Ribavirina
Impiego estetico della Tossina botulinica: importanti informazioni di sicurezza
Fibrillazione atriale non-valvolare: prevenzione dell'ictus con Rivaroxaban
Anticoagulanti: i limiti del Warfarin
Cinryze nel trattamento dell'angioedema ereditario
Trattamento dei coaguli ematici: Xarelto raccomandato dal NICE
Il rischio cardiovascolare dei farmaci antinfiammatori permane per molti anni nel post-IMA
Omega 3 non associati a beneficio nella prevenzione dell'infarto miocardico e dell'ictus nel post-IMA

MedVideo

Trattamento della macroglobulinemia di Waldenstrom
Trattamento del linfoma mantellare alla recidiva
Immunoterapia: Carcinoma polmonare non a piccole cellule, trattamento di seconda linea
Casi clinici in OncoPneumologia: Lung mass
Associazione Silvia Procopio
L'ABC della prescrizione dell'esercizio fisico nella sindrome coronarica acuta
Strength training after acute coronary syndrome
Tumore al polmone: valutazione geriatrica multidimensionale

Cerca